Vall d'Hebron Talks by VHIR 'The KDM6A/B inhibition affects viability of SMARCB1 deficient tumors through the disruption of autophagy and angiogenesis in pediatric cancer'

 Vall d'Hebron Talks by VHIR
  Sala d’actes de la planta baixa de l’Hospital Infantil i de la Dona — See in map
20/10/2023
20/10/2023 -- From 14:30h to 16:00h
Organize :
Vall d'Hebron Institut de Recerca (VHIR)
Modality: In-person
Share it:

Speaker: Octavio Alfredo Romero Ferraro, principal investigator cancer epigenetics and Biology Program - Josep Carreras Research Institute (IJC) 

In Pediatric cancer, the traditional cytotoxic therapeutic approaches are always a compromise between treatment efficacy and the risk of developing severe secondary 
effects, including new tumours during the adulthood. Our previous study demonstrates that SMARCA4 is necessary to regulate the demethylase activity of 
H3K27me3 in cancer, we discover that the inhibition of KDM6A/B is lethal specifically in SMARCA4 deficient tumors. This discovery implicates a new synthetic lethality, in which inactivating mutations in SWI/SNF members could sensitize cancer cells to specific epigenetic inhibitors affecting pediatric tumours.

Host: Miguel Segura Ginard, main researcher Childhood Cancer and Blood Disorders (VHIR)

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.